NCT02643303 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02643303
Title	A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers
Recruitment	Completed
Gender	both
Phase	Phase Ib/II
Variant Requirements	No
Sponsors	Ludwig Institute for Cancer Research
Indications	kidney cancer melanoma sarcoma breast cancer Advanced Solid Tumor head and neck squamous cell carcinoma Merkel cell carcinoma urinary bladder cancer primary cutaneous T-cell non-Hodgkin lymphoma
Therapies	Durvalumab + Poly ICLC Tremelimumab
Age Groups:	adult
Covered Countries	USA

NCT02643303
Clinical Trial Detail